PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T therapy CLIC-2201 enters human trials for Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cell…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New CAR T-Cell therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Double-Targeted immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New CAR-T study tracks immune cells in blood cancer fight
Disease control Recruiting nowThis study is for people with certain blood cancers (DLBCL, PMBCL, or ALL) that have not responded to at least two prior treatments. It will track how well the patient's own modified immune cells (CAR-T cells) grow and last in the body after infusion. The goal is to understand ho…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
Double-targeting CAR-T cells take on hard-to-treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with certain B cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The goal is to see if these specially engineere…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New combo therapy offers hope for rare blood cancer
Disease control Recruiting nowThis study tests whether adding the drug pembrolizumab to standard CAR-T cell therapy can improve outcomes for people with a rare type of lymphoma (PMBCL) that has come back or not responded to prior treatment. About 35 adults will receive the combination and be monitored for 6 m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New gene therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New CAR-T therapy aims to control aggressive blood cancer
Disease control Recruiting nowThis study tests a new treatment called TC011, which uses a patient's own immune cells (CAR-T cells) to fight a type of blood cancer called large B-cell lymphoma. The trial is for adults whose cancer has come back or not responded to at least two prior treatments. The goal is to …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New CAR T-Cell therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis trial tests a new treatment called WZTL-002 for people with large B-cell lymphoma that came back or didn't get better after standard chemo. It uses the patient's own immune cells, modified to fight cancer, and is given as a one-time infusion. About 60 adults aged 18 to 75 wi…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Lifestyle makeover for lymphoma survivors: a new hope for better living?
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma. It involves 552 adults aged 18-50 who have been in remission for 3 to 10 years. Participants will either receive the lifestyle plan o…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated May 14, 2026 12:06 UTC